- SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vas…
Number of the records: 1  

SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy

  1. TitleSKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy / G. Shen ... [et al.]
    Another responsib. Shen, G. (Author)
    Li, Y. (Author)
    Du, T. (Author)
    Shi, G. (Author)
    Dai, L. (Author)
    Chen, X. (Author)
    Zheng, R. (Author)
    Li, W. (Author)
    Su, X. (Author)
    Zhang, S. (Author)
    Wei, Y. (Author)
    Yang, S. (Author)
    Deng, H. (Author)
    Translated titleSKLB1002, nový inhibítor VEGFR 2 receptora signalizácie, indukuje normalizáciu vaskulatúry a cielene zvyšuje účinnosť systémovo podávanej chemoterapie
    Phys.des.ilustr., grafy, obr.
    NoteBibliogr. odkazy. Res. angl.
    In Neoplasma. -- ISSN 0028-2685. -- Vol. 59, no. 5 (2012), s. 486-493
    Call numberC 720
    MeSH Subject nádory experimentálne - farmakoterapia - patológia
    faktory rastové endotelové cievne
    inhibítory angiogenézy
    receptor 2 pre cievny endotelový rastový faktor - antagonisty a inhibítory - použitie terapeutické
    neovaskularizácia patologická
    mikrocievy - účinky liekov
    metastázy nádorové - ultraštruktúra
    hypoxia bunková - účinky liekov
    doxorubicín
    modely zvieracie
    Keywords chemoterapia * vaskulatúra nádoru
    LanguageEnglish
    CountrySlovakia
    DatabaseARTICLES
    article

    article

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.